56 related articles for article (PubMed ID: 38468503)
1. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
3. Combination tumor-treating fields treatment for patients with metastatic non-small cell lung cancer: A cost-effectiveness analysis.
Liu K; Zhu Y; Zhu H; Zeng M
Cancer Med; 2024 Mar; 13(5):e7070. PubMed ID: 38468503
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract][Full Text] [Related]
8. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Leal T; Kotecha R; Ramlau R; Zhang L; Milanowski J; Cobo M; Roubec J; Petruzelka L; Havel L; Kalmadi S; Ward J; Andric Z; Berghmans T; Gerber DE; Kloecker G; Panikkar R; Aerts J; Delmonte A; Pless M; Greil R; Rolfo C; Akerley W; Eaton M; Iqbal M; Langer C;
Lancet Oncol; 2023 Sep; 24(9):1002-1017. PubMed ID: 37657460
[TBL] [Abstract][Full Text] [Related]
9. First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis.
Zhu Y; Liu K; Yang Q; Zeng M; Peng L
Front Public Health; 2023; 11():1028202. PubMed ID: 37006537
[TBL] [Abstract][Full Text] [Related]
10. Cancer statistics, 2023.
Siegel RL; Miller KD; Wagle NS; Jemal A
CA Cancer J Clin; 2023 Jan; 73(1):17-48. PubMed ID: 36633525
[TBL] [Abstract][Full Text] [Related]
11. First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.
Zhu Y; Liu K; Ding D; Peng L
Clin Genitourin Cancer; 2023 Jun; 21(3):417.e1-417.e10. PubMed ID: 36529626
[TBL] [Abstract][Full Text] [Related]
12. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
Husereau D; Drummond M; Augustovski F; Briggs AH; Carswell C; Caulley L; Chaiyakunapruk N; de Bekker-Grob E; Greenberg D; Loder E; Mauskopf J; Mullins CD; Petrou S; Pwu RF; Staniszewska S;
BJOG; 2022 Feb; 129(3):336-344. PubMed ID: 35014160
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Ding D; Hu H; Li S; Zhu Y; Shi Y; Liao M; Liu J; Tian X; Liu A; Huang J
J Natl Compr Canc Netw; 2021 Aug; 19(10):1141-1147. PubMed ID: 34348237
[TBL] [Abstract][Full Text] [Related]
14. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
Herbst RS; Garon EB; Kim DW; Cho BC; Gervais R; Perez-Gracia JL; Han JY; Majem M; Forster MD; Monnet I; Novello S; Gubens MA; Boyer M; Su WC; Samkari A; Jensen EH; Kobie J; Piperdi B; Baas P
J Thorac Oncol; 2021 Oct; 16(10):1718-1732. PubMed ID: 34048946
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]